血清肿瘤标志物YKL-40与乳腺癌预后关系的研究

目的：探讨血清YKL-40水平与乳腺癌预后相关因素的关系。方法：采用酶联免疫吸附试验测定乳腺癌患者（实验组）及健康者（对照组）各40例的血清YKL-40水平,比较YKL-40水平在不同年龄、肿瘤直径、淋巴结转移、病理类型及TNM分期患者间的差异。结果：乳腺癌患者血清YKL-40水平明显高于健康对照组（P〈0.05）。肿瘤直径〉2 cm患者YKL-40水平明显高于直径≤2 cm组患者（P〈0.01）。淋巴结转移阳性患者血清YKL-40水平明显高于淋巴结转移阴性患者（P〈0.05）。随着肿瘤TNM分期进展,血清YKL-40水平逐渐升高（P〈0.01）。不同年龄及病理类型患者间血清YKL-40水平无明显差异。结论：血清YKL-40水平与乳腺癌预后相关,可望成为乳腺癌新的肿瘤标志物及治疗靶点。

Research of serum YKL-40 levels and prognosis in patients with breast cancer

Objective: To investigate the value of serum YKL-40 in the prognosis of breast cancer.Methods: Enzyme-linked mimuunosorbent assay(ELISA) was used to measure serum levels of YKL-40 in 40 patients with breast cancer and 40 healthy females cntrols for medical examination.The differences of serum YKL-40 levels was compared in the parameters of age,tumor diameter,the amount of transferred lymph nodes,pathological type and TNM stage.Results: The serum YKL-40 levels in patients with breast cancer was higher than that in healthy female controls(P<0.05).Serum YKL-40 levels were also higher in patients with tumour size >2 cm(P<0.05) and transferred lymph node(P<0.01).The serum YKL-40 levels increased with the advancement in TNM stage.The mean follow-up time was 4.5 years(range: 3~6 years).The recurrence was seen in 3 patients,and two died of distant metastasis(one in brain,another in lung and liver).Conclusion: The serum YKL-40 levels are correlative with progonosis of patients with breast cancer,and may be a promosing tumor marker and target for molecular targeted therapy.